Below are the most recent publications written about "Proto-Oncogene Proteins c-mdm2" by people in Profiles.
-
von Jan J, Timonen S, Braun T, Jiang Q, Ianevski A, Peng Y, McConnell K, Sindaco P, M?ller TA, P?tzer S, Klepzig H, Jungherz D, Dechow A, Wahnschaffe L, Giri AK, Kankainen M, Kuusanm?ki H, Neubauer HA, Moriggl R, Mazzeo P, Schmidt N, Koch R, Hallek M, Chebel A, Armisen D, Genestier L, Bachy E, Mishra A, Schrader A, Aittokallio T, Mustjoki S, Herling M. Optimizing drug combinations for T-PLL: restoring DNA damage and P53-mediated apoptotic responses. Blood. 2024 10 10; 144(15):1595-1610.
-
Adams CM, Mitra R, Xiao Y, Michener P, Palazzo J, Chao A, Gour J, Cassel J, Salvino JM, Eischen CM. Targeted MDM2 Degradation Reveals a New Vulnerability for p53-Inactivated Triple-Negative Breast Cancer. Cancer Discov. 2023 05 04; 13(5):1210-1229.
-
Thadi A, Morano WF, Khalili M, Babcock BD, Shaikh MF, Foster DS, Piazza Y, Gleeson EM, Goldstein E, Steele L, Campbell PM, Lin BO, Pincus MR, Bowne WB. Molecular Targeting of H/MDM-2 Oncoprotein in Human Colon Cancer Cells and Stem-like Colonic Epithelial-derived Progenitor Cells. Anticancer Res. 2021 Jan; 41(1):27-42.
-
Yee K, Papayannidis C, Vey N, Dickinson MJ, Kelly KR, Assouline S, Kasner M, Seiter K, Drummond MW, Yoon SS, Lee JH, Blotner S, Jukofsky L, Pierceall WE, Zhi J, Simon S, Higgins B, Nichols G, Monnet A, Muehlbauer S, Ott M, Chen LC, Martinelli G. Murine double minute 2 inhibition alone or with cytarabine in acute myeloid leukemia: Results from an idasanutlin phase 1/1b study?. Leuk Res. 2021 01; 100:106489.
-
Shen H, Wang GC, Li X, Ge X, Wang M, Shi ZM, Bhardwaj V, Wang ZX, Zinner RG, Peiper SC, Aplin AE, Jiang BH, He J. S6K1 blockade overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer. Oncogene. 2020 12; 39(49):7181-7195.
-
Thadi A, Lewis L, Goldstein E, Aggarwal A, Khalili M, Steele L, Polyak B, Seydafkan S, Bluth MH, Ward KA, Styler M, Campbell PM, Pincus MR, Bowne WB. Targeting Membrane HDM-2 by PNC-27 Induces Necrosis in Leukemia Cells But Not in Normal Hematopoietic Cells. Anticancer Res. 2020 Sep; 40(9):4857-4867.
-
Thadi A, Gleeson EM, Khalili M, Shaikh MF, Goldstein E, Morano WF, Daniels LM, Grandhi N, Glatthorn H, Richard SD, Campbell PM, Sarafraz-Yazdi E, Pincus MR, Bowne WB. Anti-Cancer Tumor Cell Necrosis of Epithelial Ovarian Cancer Cell Lines Depends on High Expression of HDM-2 Protein in Their Membranes. Ann Clin Lab Sci. 2020 Sep; 50(5):611-624.
-
Olivos DJ, Perrien DS, Hooker A, Cheng YH, Fuchs RK, Hong JM, Bruzzaniti A, Chun K, Eischen CM, Kacena MA, Mayo LD. The proto-oncogene function of Mdm2 in bone. J Cell Biochem. 2018 11; 119(11):8830-8840.
-
Feeley KP, Adams CM, Mitra R, Eischen CM. Mdm2 Is Required for Survival and Growth of p53-Deficient Cancer Cells. Cancer Res. 2017 07 15; 77(14):3823-3833.
-
Eischen CM. Role of Mdm2 and Mdmx in DNA repair. J Mol Cell Biol. 2017 02 01; 9(1):69-73.